The Clatterbridge Cancer Centre
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 17 June 2019

Re: Freedom of Information Request
Ref: 135- 2019

Thank you for your email dated 21st May 2019 requesting various information regarding patient treatments and clinical trials figures.

The information that you require is as follows:

Please note in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000.The areas where this exemption has been applied are shown below:

1 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non-small cell Lung Cancer (NSCLC) with the following:

Points of note for this response:

- ***Patients may have had more than one treatment type in the previous 6 months.***

Paclitaxel	**Exempt under S.40**
Gemcitabine	0
Osimertinib	17
Carboplatin and Pemetrexed	20
Cisplatin and Pemetrexed	10
Pembrolizumab monotherapy	178

Pembrolizumab in combination	43
Atezolizumab	36
Nivolumab	13
Other active systemic anti-cancer therapy	364

2a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Non-Small Cell Lung cancer patients?

Yes, CCC does participate in ongoing clinical trials for the treatment of Metastatic Non-Small Cell Lung cancer patients

2b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials?

Project Full title	Recruited (total)
A Phase III, open-label, multicentre, randomised study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment-naive advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy.	**Exempt under S.40**
A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer(NSCLC)	**Exempt under S.40**

3 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the following:

Points of note for this response:

- ***Patients may have had more than one treatment type in the previous 6 months.***

Cetuximab not in combination with FOLFIRI or FOLOX	73
Cetuximab in combination with FOLFIRI	32
Cetuximab in combination with FOLFOX	7
Panitumumab not in combination with FOLFIRI or	**Exempt under S.40**

FOLFOX	
Panitumumab in combination with FOLFIRI	**Exempt under S.40**
Panitumumab in combination with FOLFOX	**Exempt under S.40**
Nivolumab	0
Aflibercept	0
Bevacizumab	**Exempt under S.40**
Ramucirumab	0
Regorafenib	0
Sorafenib	0
Other active systemic anti-cancer therapy (e.g. 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU)	778

3a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Colorectal cancer patients?

Yes, CCC does participate in ongoing clinical trials for the treatment of Colorectal cancer patients.

3b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials?

Project Full title	Recruited (total)
EPOCH: A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy	**Exempt under S.40**
PLATO - PersonaLising Anal cancer radioTherapy dOse - Incorporating Anal Cancer Trials (ACT) ACT3, ACT4 and ACT5	**Exempt under S.40**
European phase III study comparing, in association with neoadjuvant chemoradiotherapy, a radiation dose escalation using 2 different approaches: External Beam Radiation Therapy versus endocavitary Radiation Therapy with Contact XRay Brachytherapy 50 kV for patients with rectal adenocarcinoma cT2-T3 a,b < 5cm in diameter in distal and middle rectum	7

4 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Head and Neck Cancer (Squamous Cell Carcinoma)?

136 patients

4a – If your Trust is able to split these patients, how many are locally advanced and how many are recurrent and or metastatic Head and Neck Cancer patients?

Unfortunately, CCC only collect staging upon presentation and are therefore unable split this information into locally advanced and recurrent metastatic at present.

4b – Of the Head and Neck cancer patients please split by their current drug treatment (if you are unable to split by locally advanced and recurrent please state the total)

Points of note for this response:

- ***CCC only collect staging upon presentation so are unable split this information into locally advanced and recurrent metastatic at present.***
- ***It has not been stated which histology groups to include (as above) so CCC have included all histology types.***
- ***Patients may have had more than one treatment type in the previous 6 months.***
- ***For radiotherapy alone – this is to primary disease only.***

Carboplatin (only or in combination with 5-FU)	Carboplatin alone = 6 Carboplatin with 5-FU = 10
Cisplatin (only or in combination with 5-FU)	Cisplatin alone = **Exempt under S.40** Cisplatin with 5-FU = 20
Cetuximab with / without chemotherapy	Cetuximab alone = **Exempt under S.40** Cetuximab with SACT = **Exempt under S.40**
Cetuximab with radiotherapy	**Exempt under S.40**
Pembrolizumab monotherapy	**Exempt under S.40**
Pembrolizumab with chemotherapy	0
Nivolumab	24
Docetaxel (only or in combination with 5-FU)	**Exempt under S.40**

Fluorouracil (5-FU)	0
Radiotherapy only	116
Other	119

4c – Does your Health Trust participate in any ongoing clinical trials for the treatment of Head and Neck cancer patients?

Yes, CCC does participate in ongoing clinical trials for the treatment of Head and Neck cancer patients.

4d – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials?

Project Full title	Recruited (total)
A randomised placebo-controlled trial of synchronous NIMorazole versus RADiotherapy alone in patients with locally advanced head and neck squamous cell carcinoma not suitable for synchronous chemotherapy or cetuximab	**Exempt under S.40**
A Phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer	8
Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer	**Exempt under S.40**
An Open-Label, Multicenter, Phase 1/2 Study of RPI as a Single Agent and in Combination with Immune Checkpoint Blockade or Other Standard of Care Regimens in Patients with Solid Tumors	**Exempt under S.40**
A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONT LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK	**Exempt under S.40**

5 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Urothelial Carcinoma UCC) with the following:

Points of note for this response:

- ***Below patients with Transitional Cell Carcinoma Only (TCC = UCC)***
- ***Patients may have had more than one treatment type in the previous 6 months.***

Cisplatin single agent	0
Cisplatin in combination with another agent	32
Carboplatin single agent	0
Carboplatin in combination with another agent	0
Nivolumab	0
Pembrolizumab	17
Atezolizumab	10
Other active systemic anti-cancer therapy	29

5a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients?

Yes, CCC does participate in ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients.

5b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials?

Project Full title	Recruited (total)
A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy	10
Quality of Life After Bladder Cancer (Q-ABC): A comparison of patient related outcomes following radical surgery and radiotherapy	6
A NON-INTERVENTIONAL, MULTICENTER, MULTIPLE COHORT STUDY INVESTIGATING THE OUTCOMES AND SAFETY OF ATEZOLIZUMAB UNDER REAL-WORLD CONDITIONS IN PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE	**Exempt under S.40**

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

https://www.surveymonkey.co.uk/r/H39RFMM